ArticleBritish journal of cancer2026
Integrating lymphovascular invasion and ypTNM staging system for esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy and surgery: a multi-institutional analysis.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Predictive model based on folate receptor-positive circulating tumor cells in neoadjuvant immunochemotherapy for esophageal cancer.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeEvidence on the prognostic and staging effects of lymphovascular invasion (LVI) after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (ESCC) is limited. We aimed to determine the prognostic value of LVI and develop a modified post-neoadjuvant pathologic staging (ypStage) system integrating LVI and ypTNM stage to improve risk stratification.
methodsThis multi-institutional study included patients with ESCC receiving neoadjuvant chemoradiotherapy and R0 resection. Recursive partitioning analysis (RPA) was conducted to derive prognostic groupings. A modified ypStage system was developed, validated, and compared with ypTNM stage.
resultsA total of 931 patients were divided into training (n = 565) and external validation (n = 366) cohorts. LVI was present in 115 patients (12.4%). LVI was an independent predictor of survival and disease recurrence, with hazard ratios of 1.70 for overall survival and 1.74 for recurrence-free survival. By integrating LVI status and ypTNM stage, nonmetastatic ESCC were classified into three stages with distinct prognoses. The proposed RPA stage provided superior hazard consistency, hazard discrimination, sample size balance, and outcome prediction over ypTNM stage.
conclusionsLVI was a strong prognostic factor, independent of the current ypTNM stage in ESCC. We developed an RPA-based ypStage system integrating LVI status and ypTNM stage that exhibited good prognostic performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.